News Release 

Synthetic biology and machine learning speed the creation of lab-grown livers

University of Pittsburgh

Research News


IMAGE: Associate professor of pathology, University of Pittsburgh School of Medicine. view more 

Credit: Arizona State University

PITTSBURGH, Dec. 7, 2020 - Researchers at the University of Pittsburgh School of Medicine have combined synthetic biology with a machine-learning algorithm to create human liver organoids with blood- and bile-handling systems. When implanted into mice with failing livers, the lab-grown replacement livers extended life.

The study, published today in Cell Systems, shows that it's possible to trigger and speed up the maturation of a lab-grown organ without sacrificing precision or control.

"Pregnancy is nine months--it takes that long and even months after birth for new organs to mature--but if a person needs a liver, they may not be able to wait that long," said study author Mo Ebrahimkhani, M.D., associate professor of pathology and bioengineering, and member of the Pittsburgh Liver Research Center and the McGowan Institute for Regenerative Medicine. "We showed it's possible to get human liver tissue with four main cell types and vasculature in 17 days. We can mature tissue almost to the third trimester in only three months."

Other groups have attempted to coax organoid maturation in a dish using growth factors, but it's expensive, inconsistent and prone to human error, Ebrahimkhani said. Often, there are unwanted tissue or cell types--such as intestine or brain cells growing in the middle of what should be solid liver.

Using genetic engineering is cleaner but also more complex to orchestrate. So, Ebrahimkhani partnered with Patrick Cahan, Ph.D., at Johns Hopkins University to use a machine-learning system that can reverse engineer the genes necessary for human liver maturation.

Then, Ebrahimkhani together with his collaborator at Pitt, Samira Kiani, M.D., applied genetic engineering techniques, including CRISPR, to turn a mass of immature liver tissue--originally derived from human stem cells--into what the team calls "designer liver organoids."

The more mature the organoids got, the more capillaries and rudimentary bile duct cells snaked their way through the thin sheet of tissue, and the more closely the function of the tiny organ rivaled its full-size natural human model. Energy storage, fat accumulation, chemical transport, enzyme activity and protein production were all closer to adult human liver function, though still not a perfect match.

Ebrahimkhani imagines designer organoids having three main uses: drug discovery, disease modeling and organ transplant. Since the stem cells can come from the patient's own body, lab-grown organs could be personalized, so there would be no threat of immune rejection.

When transplanted into mice with damaged livers, Ebrahimkhani's designer liver organoids successfully integrated into the animals' bodies and continued to work--producing human proteins that showed up in the animals' blood and prolonging the animals' lives.

This is a proof-of-principle to show that it's possible, Ebrahimkhani said. The technique could potentially go much further.

"Our reference was a nature-designed human liver, but you can go after any design you like. For instance, you can make a genetic switch that protects the tissue from a virus, target the DNA of the virus and destroy it," Ebrahimkhani said. "That sets this method apart."


Additional authors on the study include co-first authors Jeremy Velazquez and Ryan LeGraw, as well as Farzaneh Moghadam, Ph.D., Joseph Maggiore, Joshua Hislop and Silvia Liu, Ph.D., of Pitt; Yuqi Tan of Johns Hopkins; Jacquelyn Kilbourne and Christopher Plaisier, Ph.D., of Arizona State University; and Davy Cats and Susana Chuva de Sousa Lopes, Ph.D., of Leiden University Medical Center.

Several of the authors have submitted a patent (WO2019237124) for the methods described in this paper.

This study was supported by the National Institute of Biomedical Imaging and Bioengineering (R01 EB028532 and R01 EB024562), the National Heart, Lung, and Blood Institute (R01 HL141805), Arizona Biomedical Research Council (ADHS16-162402), National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK120531) and the National Institute of General Medical Sciences (T32GM008208 and R35GM124725).

To read this release online or share it, visit [when embargo lifts].

About the University of Pittsburgh School of Medicine

As one of the nation's leading academic centers for biomedical research, the University of Pittsburgh School of Medicine integrates advanced technology with basic science across a broad range of disciplines in a continuous quest to harness the power of new knowledge and improve the human condition. Driven mainly by the School of Medicine and its affiliates, Pitt has ranked among the top 10 recipients of funding from the National Institutes of Health since 1998. In rankings recently released by the National Science Foundation, Pitt ranked fifth among all American universities in total federal science and engineering research and development support.

Likewise, the School of Medicine is equally committed to advancing the quality and strength of its medical and graduate education programs, for which it is recognized as an innovative leader, and to training highly skilled, compassionate clinicians and creative scientists well-equipped to engage in world-class research. The School of Medicine is the academic partner of UPMC, which has collaborated with the University to raise the standard of medical excellence in Pittsburgh and to position health care as a driving force behind the region's economy. For more information about the School of Medicine, see

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.